1 / 9

Management

Management. Antiepileptic Drug Therapy Goal: completely prevent seizures without causing untoward side effects Treat the underlying conditions Reverse the problem and prevent its recurrence. Drug of Choice for Epilepsy. Patient’s Medication Upon Admission. ILAE Treatment Guidelines, 2006.

hamal
Download Presentation

Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management • Antiepileptic Drug Therapy • Goal: completely prevent seizures without causing untoward side effects • Treat the underlying conditions • Reverse the problem and prevent its recurrence

  2. Drug of Choice for Epilepsy Patient’s Medication Upon Admission ILAE Treatment Guidelines, 2006 Effectiveness-outcome evidence Based on RCT efficacy and effectiveness evidence, CBZ, LTG, OXC, PB, PHT, TPM, and VPA are possibly efficacious/effective as initial monotherapy for adults with GTC seizures and may be considered for initial therapy in selected situations (level C) (Glauser, et al. 2006) • Phenytoin (Dilantin) 100mg/cap TID Glauser, T, ElinorBM, BlaiseBs,et. al. "ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes." (International League Against Epilepsy) 27, no. 7 (2006): 1094 -1120.

  3. Maintenance Medications Home Medications Current Perspectives in Epilepsy Treatment: Focus on Monotherapy, 2006 Initial treatment of epilepsy should begin with AED monotherapy If initial trial fails, try monotherapy with a second AED Combination therapy should be considered only if the patient fails at least 2 monotherapytrials • Phenytoin 100mg/cap TID • Levetiracetam 500mg/tab BID • Citicoline 1gm/tab BID • ASA 80 gm/tab OD Pellock, John, and Michael Privitera. Current Perspectives in Epilepsy Treatment: Focus on Monotherapy. CME Discovery, USA: ArcMesa Educators and Scinexa, LLC., 2006.

  4. Maintenance Medications Home Medications ILAE Treatment Guidelines, 2006 For patients with newly diagnosed or untreated epilepsy which AEDs have the best evidence for use as initial monotherapy? RCT efficacy and effectiveness: CBZ, LTG, OXC, PB, PHT, TPM, and VPA are possibly efficacious/effective as initial monotherapy for adults with GTC seizures and may be considered for initial therapy in selected situations (level C) (Glauser, et al. 2006) • Phenytoin 100mg/cap TID • Levetiracetam 500mg/tab BID • Citicoline 1gm/tab BID • ASA 80 gm/tab OD Glauser, T, ElinorBM, BlaiseBs,et. al. "ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes." (International League Against Epilepsy) 27, no. 7 (2006): 1094 -1120.

  5. Maintenance Medications Home Medications Current Perspectives in Epilepsy Treatment: Focus on Monotherapy, 2006 Levetiracetam Sodium channel blocker No important interactions with other antiepileptic drugs • Phenytoin 100mg/cap TID • Levetiracetam 500mg/tab BID • Citicoline 1gm/tab BID • Toward a Multimodal Neuroprotective Treatment of Stroke, 2006 • Citicoline • RCTs show that citicolineimproves neurological outcome after stroke • meta-analysis indicates that there might be an effect for the subgroup of moderate to severe ischemic strokes • Combinations with either growth factors or thrombolytics produce true synergistic effects  reduced mortality and infarct volume Pellock, John, and Michael Privitera. Current Perspectives in Epilepsy Treatment: Focus on Monotherapy. CME Discovery, USA: ArcMesa Educators and Scinexa, LLC., 2006 Fisher, Marc, AntoniDavalos, Andreas Rogalewski, et. al.Toward a Multimodal Neuroprotective Treatment of Stroke. Stroke (American Heart Association) 2006;37;1129-1136 .

  6. Post-stroke Maintenance Medications • Maintenance since Jan 2010, post stroke • ASA 80mg/tab OD • Dipyrimadole (Persantine) 200mg/tab BID • International Stroke Trial (IST, Lancet 1997;349:1569-1581) • Aspirin treated patients had slightly fewer deaths at 14 days, significantly fewer recurrent ischemic strokes at 14 days and no excess of hemorrhagic strokes • Dipyridamolefor Preventing Stroke and Other Vascular Events in Patients With Vascular Disease: An Update • Compared with control, dipyridamole had no clear effect on vascular death (RR 0.99, 95% CI, 0.87 to 1.12). • Compared with control, dipyridamoleappeared to reduce the risk of vascular events (RR 0.88, 95% CI, 0.81 to 0.95). • Routine use of dipyridamole alone as first line antiplatelet treatment is not supported. The combination of dipyridamole plus aspirin is associated with a lower risk of further vascular events than aspirin alone.

  7. Discontinuation of Anticonvulsants • Specchio and colleagues • After 2 years on a single anticonvulsant during which no seizures had occurred, the rate of relapse was 40% 2 and a half years later and 50% at 5 years after discontinuation • For patients remaining on medication, seizure recurrence rate is 20%

  8. Discontinuation of Anticonvulsants • When patient has been free of seizures for a prolonged period (?) • A safe plan, applicable to most forms of epilepsy, is to obtain an EEG whenever withdrawal of medication is contemplated. • If the tracing is abnormal by way of showing paroxysmal activity, it is generally better to continue treatment.

  9. Public Health Perspective

More Related